Replimune Group, Inc.
Replimune Group, Inc. (Nasdaq: REPL) is a clinical-stage biotechnology company developing oncolytic immunotherapies designed to kill tumors and stimulate anti-tumor immune responses. Its proprietary RPx platform uses an engineered herpes simplex virus 1, or HSV-1, to selectively replicate in tumors and express… From the company’s description.
In fiscal 2025, Replimune Group, Inc. reported a net loss of $313.94M. Operations used $280.34M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Replimune Group, Inc. does
In the company’s own words
Replimune Group, Inc. (Nasdaq: REPL) is a clinical-stage biotechnology company developing oncolytic immunotherapies designed to kill tumors and stimulate anti-tumor immune responses. Its proprietary RPx platform uses an engineered herpes simplex virus 1, or HSV-1, to selectively replicate in tumors and express immune-activating proteins. The company’s candidates are administered by direct injection into solid tumors and are being studied alone or with checkpoint inhibitors. Its lead candidate, RP1, is in development for advanced melanoma and other skin cancers; RP2 is being studied in metastatic uveal melanoma and liver cancer, while development of RP3 is not currently being pursued. The company has one business segment and no approved products. Replimune operates an approximately 63,000-square-foot U.S. manufacturing facility to supply clinical studies and potentially future commercial production. In fiscal 2026, it reported no product sales, with its business focused on research and development and clinical programs. Its website is https://www.replimune.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WOBURN, MA
- Fiscal year end
- March
- CIK
- 1737953
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Replimune Group, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Replimune Group, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Replimune Group, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Replimune Group, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Replimune Group, Inc.'s last four quarterly filings that the numbers alone won't show?”